FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
0
0
0 Tampilan·
09/21/23
Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
Menampilkan lebih banyak
0 Komentar
sort Sortir dengan